The National Comprehensive Cancer Network (NCCN) Oncology Research Program (ORP) announced initiatives for the first time to evaluate a potent and selective inhibitor of the fibroblast growth receptor (FGFR), known as futibatinib (TAS-120). Inclusive of pre-clinical, translational and clinical trials using futibatinib as monotherapy and potentially in relevant combination regiments for malignancies with FGFR 1-4 aberrations.
RFP Development Team
A group of experts within NCCN member institutions will participate in Request for Proposal (RFP) Development Team that will conduct targeted bid processes for Phase I of the project. Funding originates from a $2 million grant from Taiho Oncology.
What is Futibatinib (TAS-120)?
Futibatinib is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. It selectively and irreversibly binds to and inhibits FGFR, which may result in the inhibition of both the FGFR-mediated signal transduction pathway and tumor cell proliferation, and increased cell death in FGFR-overexpressing tumor cells, reports the National Cancer Institute (NCI). FGFR is a receptor tyrosin...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).